{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.","groups":[{"description":"All patients received ATG 1mg/kg Day-16 and then 3.5 mg/kg Day -15 Fludarabine 30mg/m2/day on days -7 to -3 Busulfan 130 mg/m2 on days -4 \\& -3 Cyclophosphamide 1.5 g/m2 on day -2 Tacrolimus begins 0.03mg/kg bid on Day -1 Stem Cell transplant on Day 0 Methotrexate 5mg/m2 given D+1, +3 and +6","id":"OG000","title":"RIC Transplant Using ATG, Busulfan, Fludarabine and Cytoxan"}],"paramType":"NUMBER","populationDescription":"20 of the patients treated on study had chimerism drawn on day 180.","reportingStatus":"POSTED","timeFrame":"180 days","title":"T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)","type":"SECONDARY","unitOfMeasure":"participants"}